Vertaling van "with information " (Nederlands → Frans) :

TERMINOLOGIE

AERRPS - acute encephalitis with refractory repetitive partial seizures
syndrome épileptique par infection fébrile

CMDH - congenital muscular dystrophy with hyperlaxity
dystrophie musculaire congénitale avec hyperlaxité

IN-CONTEXT TRANSLATIONS

BAPCOC (with FPS Public Health) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Interdepartmental network on “information society services” (with FPS Economy) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI) Working group on blood of the Belgian Federal Supreme Health Council Working group on cells, tissues and organs of the Belgian Federal Supreme Health Council
BAPCOC (with FPS Public Health) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Interdepartmental network on “information society services” (with FPS Economy) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI) Working group on blood of the Belgian Federal Supreme Health Council Working group on cells, tissues and organs of the Belgian Federal Supreme Health Council

The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but (Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”. Only 26% would choose to inform the patient outside the existing organs, and with a stronger preference on informing after the decision is taken.
The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but ( Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”.

The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.
The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.

It is also essential for rational and safe use of medicines that the information in advertising agrees with the elements approved of when the marketing authorisation (MA) for the medicine was granted. Healthcare professionals when making a therapeutic choice should not be influenced by elements that are not associated with the characteristics of the medicine.
It is also essential for rational and safe use of medicines that the information in advertising agrees with the elements approved of when the marketing authorisation (MA) for the medicine was granted. Healthcare professionals when making a therapeutic choice should not be influenced by elements that are not associated with the characteristics of the medicine.

Interdepartmental network on “information society services” cells, tissues and embryos (with FPS Public Health, KCE, RIZIV (with FPS Economy)
Interdepartmental network on “information society services” cells, tissues and embryos (with FPS Public Health, KCE, RIZIV (with FPS Economy)

Provision has been made for the organised exchange of information with the national scientific commissions which give final opinions (e.g. evaluation commissions for medicines) and with the representatives on the international scientific or regulatory committees (e.g. CHMP, CVMP, CMD(h), CMD(v), COMP, PDCO).
Provision has been made for the organised exchange of information with the national scientific commissions which give final opinions (e.g. evaluation commissions for medicines) and with the representatives on the international scientific or regulatory committees (e.g. CHMP, CVMP, CMD(h), CMD(v), COMP, PDCO).

Proactive contacts with the general and specialised press, various publications and information campaigns will be included together with future internal communication actions in a proper communication plan so as to implement a strategic communication policy as quickly as possible.
Proactive contacts with the general and specialised press, various publications and information campaigns will be included together with future internal communication actions in a proper communication plan so as to implement a strategic communication policy as quickly as possible.

The Communication & Scientific Support service assists the different departments and services of the FAMHP with internal and external communication and with information about the organisation and also acts as the FAMHP’s spokesman.
The Communication & Scientific Support service assists the different departments and services of the FAMHP with internal and external communication and with information about the organisation and also acts as the FAMHP’s spokesman.

In the first scenario, there is no significant difference between the respondents with regard to the choice of the place where the information is given (inside or outside the existing decision-making organs) according their current/past membership (or not) of the INAMI – RIZIV organs.
Only 26% would choose to inform the patient outside the existing organs, and with a stronger preference on informing after the decision is taken. In the first scenario, there is no significant difference between the respondents with regard to the choice of the place where the information is given (inside or outside the existing decision-making organs) according their current/past membership (or not) of the INAMI – RIZIV organs.

Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.